Abstract: The present invention relates to novel SMAC mimetic peptidomimetics useful for the treatment of proliferative diseases including cancer in mammals The novel SMAC mimetics are prepared by incorporating (2S,5R)-5-(5-methylfuran-2-yl)pyrrolidine-2-carboxylic acid, a novel unnatural amino acid that imparts exclusively trans amide bond geometry favourable for target protein binding. Here, the novel SMAC mimetic molecule(s) not only show its efficacy in varied cancer types but also demonstrate in vitro and in vivo efficacy against therapy resistant cancer as a single agent. The novel SMAC mimetics disclosed in the present invention binds to BIR-2 and BIR-3 domains of the XIAP and exhibit high anti-proliferative activity against variety of mammalian cancer cell lines that include but not limited to chemotherapy and TRAIL resistant cell lines.

Abstract: This invention relates to solid amorphous Compound (I) having the formula (I) and to solid amorphous dispersions comprising Compound (I) and one or more polymers or to solution formulations comprising Compound (I) and one or more co-solvents and surfactants. The formulations exhibit enhanced stability and bioavailability. This invention relates to solid amorphous dispersions comprising Compound (I) having the formula (I) and one or more polymers or to solution formulations comprising Compound (I) and one or more co-solvents and surfactants. The formulations exhibit enhanced stability and bioavailability.

Abstract: Provided are a Raman signal measuring method and apparatus which use a difference in a time scale between Raman scattered light and fluorescence. Thus, after exciting light is incident upon a target object, light scattered from the target object may be detected before the target object generates fluorescence in response to the exciting light. As a result, a Raman signal in which background fluorescence is reduced may be obtained.